Quantitative rapid free light chain test registered in Brazil

Abingdon Health is pleased to announce Seralite® – FLC Serum, which can be used to diagnose and manage patients with multiple myeloma, has been granted registration by the Brazilian Health Regulatory Agency (ANVISA)
 
 
Quantitative rapid free light chain test
Quantitative rapid free light chain test
YORK, England - May 20, 2019 - PRLog -- Seralite® – FLC is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in "real time" supporting faster decision making.

This is a key registration for Seralite® – FLC and underpins the regional strategy for Latin America. In conjunction with Seralite® – FLC Serum, Seralite® – FLC LFD Controls and the ADxLR5® Reader System have also been granted registration. Latin America has a population of 606 million people and with a market size of more than US$2.4bn is a key emerging IVD market.

With this registration in Brazil, Seralite® – FLC is now available in 73 countries worldwide. Seralite® – FLC is distributed globally (with the exception of Benelux), by Sebia, the world leader in medical diagnostics for electrophoresis.

To learn more about Seralite® – FLC please visit https://www.abingdonhealth.com/medical-diagnostics/seralite/.
End
Email:***@abingdonhealth.com Email Verified
Phone:1904406082
Tags:Rapid Test
Industry:Health
Location:York - North Yorkshire - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Abingdon Health PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share